Zimmer Biomet has launched an autograft substitute featuring the similar bone healing elements as autograft.
The PrimaGen Advanced Allograft does not have the risks associated with donor site morbidity or harvest site complications.
While Allograft is about human tissue transplanted from a donor to a patient, autograft tissue is transferred from one part of a patient’s body to another.
The company's new autograft substitute offers a combo of demineralised cortical bone fibres with verified osteoinductivity and cancellous bone.
It has been designed to provide the three essential components for bone growth and healing, including osteoconductivity, osteoinductivity and osteogenicity.
According to Zimmer, advanced donor tissue testing verified that the cells in cancellous bone providing an interconnected trabecular structure, remain viable post-thaw.
At least 750,000 cells per cubic centimetre were found to be contained in a graft of cancellous tissue, with at least 70% cell viability. Crucial to new bone formation, the cells were able to differentiate into mature osteoblasts.
Zimmer Biomet Spine, Dental, CMF and Thoracic group president Adam Johnson said: "PrimaGen Advanced Allograft was developed to overcome the limitations of other bone graft substitutes and designed to offer a real alternative to autograft.
"We are pleased to include within our Spine portfolio a graft that not only has desirable handling characteristics, but is simple and convenient to use. PrimaGen Advanced Allograft recreates the Gold Standard, while reducing the co-morbidities tied to graft harvest."
The PrimaGen Advanced Allograft is intended to be used as a substitute for allogeneic bone graft with viable donor cells for homologous use in repair, replacement, reconstruction and supplementation of recipient’s tissue in musculoskeletal defects which were either created surgically or from traumatic injury to bone.